Skip to main content
NewslettersWatchlist

Monte Rosa Therapeutics Inc(GLUE-Q)
NASDAQ

Today's Change
Real-Time Last Update Last Sale Cboe BZX Real-Time
Day Low3.92
Day High4.25
Open:4.02
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change
Realtime quote and/or trade prices are not sourced from all markets.
Select a category then submit the form to load news
Motley Fool
3 Incredible Growth Stocks That Could Soar in 2024, According to Wall Street
Barchart
Pre-Market Brief: Stocks Climb As Investors Await FOMC Minutes
Globe Newswire
Monte Rosa Therapeutics Reports Second Quarter 2022 Financial Results and Business Updates
Globe Newswire
Monte Rosa Therapeutics Reports First Quarter 2022 Financial Results and Business Updates
Globe Newswire
Monte Rosa Therapeutics Presents Preclinical Data Highlighting Potential of GSPT1-directed Molecular Glue Degrader MRT-2359 to Target Myc-driven Cancers at AACR Annual Meeting 2022
Globe Newswire
Monte Rosa Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Business Updates
Globe Newswire
Monte Rosa Therapeutics Announces Participation in Upcoming Investor Conferences
Globe Newswire
Monte Rosa Therapeutics and Yeda, the commercial arm of the Weizmann Institute of Science, Announce License and Research Collaboration to Accelerate Discovery of Novel Covalent Molecular Glue Degraders
Globe Newswire
Monte Rosa Therapeutics to Present at the 40th Annual J.P. Morgan Healthcare Conference
Globe Newswire
Monte Rosa Therapeutics Appoints Jullian G. Jones, Ph.D., J.D., MBA, as Chief Business Officer
Globe Newswire
Monte Rosa Therapeutics to Participate in Piper Sandler 33rd Annual Virtual Healthcare Conference
Globe Newswire
Monte Rosa Therapeutics Announces First Development Candidate and Reports Third Quarter 2021 Financial Results and Business Updates
Globe Newswire
Monte Rosa Therapeutics to Present at 4th Annual Targeted Protein Degradation Summit
Globe NewsWire
Monte Rosa Therapeutics to Present Late-breaking Preclinical Data on Targeting GSPT1 for Myc-driven Cancers at AACR-NCI-EORTC Virtual International Conference
Globe NewsWire
Monte Rosa Therapeutics Announces Addition to Russell 2000® and Russell 3000® Indexes
Globe NewsWire
Monte Rosa Therapeutics to Participate in Morgan Stanley 19th Annual Global Healthcare Conference
Globe NewsWire
Monte Rosa Therapeutics Reports Second Quarter 2021 Financial Results and Highlights Pipeline and Business Progress
Globe NewsWire
Monte Rosa Therapeutics Announces Pricing of Initial Public Offering

Profile

Monte Rosa Therapeutics Inc. is a biotechnology company. It involved in developing a portfolio of novel small molecule precision medicines which employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. Monte Rosa Therapeutics Inc. is based in BOSTON.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2024.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).

Copyright © 2024 Morningstar. All Rights Reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Past performance is no guarantee of future results.